TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30241511

Group type: EXPERIMENTAL
Intervention: Tele-monitoring (TM)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Conventional hospital monitoring (HM)
Number of subjects: 50
Study: 28577680

Group type: EXPERIMENTAL
Intervention: Udenafil 87.5 mg bid
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Udenafil (various doses: 37.5, 87.5, 125 mg daily, 37.5 and 87.5 mg bid)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control cohort (exercise testing only)
Number of subjects: 36
Study: 23954983

Group type: EXPERIMENTAL
Intervention: Stress-management intervention (SMI)
Number of subjects: 174

Group type: COMPARATOR
Intervention: Waiting control group (CG)
Number of subjects: 174
Study: 24127442

Group type: EXPERIMENTAL
Intervention: Gemtuzumab ozogamicin (GO)
Number of subjects: 472

Group type: COMPARATOR
Intervention: Standard chemotherapy (no GO)
Number of subjects: 472
Study: 20852004

Group type: EXPERIMENTAL
Intervention: Pantoprazole 20 mg once daily
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pantoprazole 40 mg once daily
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pantoprazole (both doses)
Number of subjects: 0
Study: 18501865

Group type: EXPERIMENTAL
Intervention: Mood and Feelings Questionnaire, short form (MFQ‐SF)
Number of subjects: 1375

Group type: EXPERIMENTAL
Intervention: Childhood Anxiety Sensitivity Index (ASI)
Number of subjects: 1375
Study: 17006117

Group type: EXPERIMENTAL
Intervention: Chlorhexidine 0.2% wt/vol oral rinse
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Benzydamine 0.15% wt/vol oral rinse
Number of subjects: 14
Study: 14602795

Group type: EXPERIMENTAL
Intervention: Recombinant GH (5 micro g/kg.d)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo administration
Number of subjects: 12

Group type: COMPARATOR
Intervention: Vehicle treatment
Number of subjects: 12

Group type: COMPARATOR
Intervention: GH receptor antagonism
Number of subjects: 12
Study: 10765074

Group type: EXPERIMENTAL
Intervention: Transrectal power Doppler sonography (TRPDS) measuring resistive index (RI)
Number of subjects: 140
Study: 9303669

Group type: EXPERIMENTAL
Intervention: Passive distribution of informative leaflets on NSAIDs
Number of subjects: 348

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 348
Study: 8222304

Group type: EXPERIMENTAL
Intervention: Intralesional adrenaline and heater probe
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 100
Study: 2946507

Group type: EXPERIMENTAL
Intervention: Isradipine 10 mg b.i.d.
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Isradipine 20 mg b.i.d.
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 29320770

Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 1255

Group type: EXPERIMENTAL
Intervention: Cardiovascular disease
Number of subjects: 1255

Group type: EXPERIMENTAL
Intervention: Peripheral vascular disease
Number of subjects: 1255

Group type: EXPERIMENTAL
Intervention: Higher hemoglobin A1c (HbA1c)
Number of subjects: 1255

Group type: EXPERIMENTAL
Intervention: Loss of self-dependency
Number of subjects: 1255

Group type: EXPERIMENTAL
Intervention: Higher albumin
Number of subjects: 1255

Group type: EXPERIMENTAL
Intervention: Body mass index (BMI)
Number of subjects: 1255
Study: 25916256

Group type: EXPERIMENTAL
Intervention: Pain expectation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Average pain intensity
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Moderate to severe pain intensity
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High composite pain index
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Satisfaction with pain level
Number of subjects: 0
Study: 24588644

Group type: EXPERIMENTAL
Intervention: PTEN protein
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ci‐VSP
Number of subjects: 0
Study: 23776123

Group type: EXPERIMENTAL
Intervention: Neonatal weight gain (NWG)
Number of subjects: 13840

Group type: EXPERIMENTAL
Intervention: Head circumference gain (HCG)
Number of subjects: 13840
Study: 20230914

Group type: EXPERIMENTAL
Intervention: Soy isoflavones 200mg daily
Number of subjects: 283

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 283
Study: 19102123

Group type: EXPERIMENTAL
Intervention: Dynamic acoustic neural stimulus (customized to each patient's audiometric profile)
Number of subjects: 470
Study: 16911937

Group type: EXPERIMENTAL
Intervention: DDS implantation through the portal vein (P-implanted group)
Number of subjects: 190

Group type: EXPERIMENTAL
Intervention: DDS implantation through the hepatic artery (A-implanted group)
Number of subjects: 190

Group type: EXPERIMENTAL
Intervention: DDS implantation through both the hepatic artery and portal vein (A+P-implanted group)
Number of subjects: 190

Group type: COMPARATOR
Intervention: Control group (subgroup b)
Number of subjects: 190

Group type: COMPARATOR
Intervention: Control group (subgroup c)
Number of subjects: 190
Study: 12878791

Group type: EXPERIMENTAL
Intervention: Recent treatment protocol (surgery, craniospinal irradiation, 4 courses of chemotherapy including VCR, VP, CBDCA, CTX, IF, CDDP, followed by 8 courses of maintenance chemotherapy with VCR, CDDP, CCNU)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Earlier treatment protocol (surgery and radiotherapy followed by chemotherapy)
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Recent treatment protocol for high-risk patients
Number of subjects: 77

Group type: COMPARATOR
Intervention: Earlier treatment protocol for high-risk patients
Number of subjects: 77
Study: 11049140

Group type: EXPERIMENTAL
Intervention: Exercise treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 9004971

Group type: EXPERIMENTAL
Intervention: Functional Reach (FR)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Single Leg Stance (SLS)
Number of subjects: 28
Study: 7875183

Group type: EXPERIMENTAL
Intervention: 200 mg ibopamine (IBO)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: 20 mg isosorbide mononitrate (ISMN)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Both IBO and ISMN
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 2831248

Group type: EXPERIMENTAL
Intervention: Test diet (1660 mg phosphorus, 420 mg calcium)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control diet (820 mg calcium, 930 mg phosphorus)
Number of subjects: 16
Study: 30571419

Group type: EXPERIMENTAL
Intervention: Dual-task balance/mobility training
Number of subjects: 84

Group type: COMPARATOR
Intervention: Single-task balance/mobility group
Number of subjects: 84

Group type: COMPARATOR
Intervention: Upper-limb exercise (control)
Number of subjects: 84
Study: 28981760

Group type: EXPERIMENTAL
Intervention: Management of possible serious bacterial infection (PSBI) for newborns at health posts by Health Extension Workers (HEWs) with additional equipment, support, and supervision.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group receiving improved implementation of the Health Extension Programme without additional PSBI management.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intervention group receiving PSBI management.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intervention group costs.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group costs.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cost-effectiveness of the intervention.
Number of subjects: 0
Study: 28073387

Group type: EXPERIMENTAL
Intervention: Surgery
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: No surgery
Number of subjects: 149

Group type: COMPARATOR
Intervention: Control (age-matched children without recurrent acute otitis media)
Number of subjects: 149
Study: 23969321

Group type: EXPERIMENTAL
Intervention: Fresh kimchi (1‐day‐old)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Fermented kimchi (10‐day‐old)
Number of subjects: 21
Study: 21839609

Group type: EXPERIMENTAL
Intervention: Microincision with continuous mode
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Microincision with pulse mode
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Microincision with burst mode
Number of subjects: 180

Group type: COMPARATOR
Intervention: Small-incision coaxial phacoemulsification
Number of subjects: 180
Study: 19593941

Group type: EXPERIMENTAL
Intervention: 1 gram of fish oil daily for 6 months (containing 180 mg eicosapentaenoic acid and 120 mg docosahexaenoic acid)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group (no supplementation)
Number of subjects: 120
Study: 17415202

Group type: EXPERIMENTAL
Intervention: Cerebral infarction
Number of subjects: 3567

Group type: COMPARATOR
Intervention: Control group (no cerebral infarction)
Number of subjects: 3567
Study: 15136062

Group type: EXPERIMENTAL
Intervention: L-arginine (6g per day)
Number of subjects: 29

Group type: COMPARATOR
Intervention: None (control group)
Number of subjects: 29
Study: 11394697

Group type: EXPERIMENTAL
Intervention: Continuous veno‐venous hemodiafiltration (CVVHDF)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Intermittent hemodialysis (IHD)
Number of subjects: 88
Study: 10193230

Group type: EXPERIMENTAL
Intervention: EMLA patch
Number of subjects: 180

Group type: COMPARATOR
Intervention: Placebo patch with infiltration analgesia (2 ml lignocaine 2% with adrenaline)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Placebo patch
Number of subjects: 180
Study: 7602741

Group type: EXPERIMENTAL
Intervention: Binkhorst formula
Number of subjects: 887

Group type: COMPARATOR
Intervention: SRK Linear Regression formula
Number of subjects: 887
Study: 2403736

Group type: EXPERIMENTAL
Intervention: Sotalol
Number of subjects: 0
Study: 354512

Group type: EXPERIMENTAL
Intervention: Monomycin combined with Eleutherococcus (1st group)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Monomycin alone (2nd group)
Number of subjects: 100
Study: 31704437

Group type: EXPERIMENTAL
Intervention: Supervised, progressive treadmill walking exercise (TMWX) training 3 times/week for 12 weeks, progressing from 15-min light-to-moderate intensity to 40-min vigorous intensity
Number of subjects: 88

Group type: COMPARATOR
Intervention: Supervised, minimal intensity, stretching-and-resistance exercise
Number of subjects: 88
Study: 28719555

Group type: EXPERIMENTAL
Intervention: Nonoperative treatment
Number of subjects: 76
Study: 26317258

Group type: EXPERIMENTAL
Intervention: Continuous local wound infusion treatment in addition to WHO standard pain management protocol (Group 1)
Number of subjects: 42

Group type: COMPARATOR
Intervention: WHO standard pain management protocol (Group 2)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Continuous local wound infusion treatment (Group 1)
Number of subjects: 42
Study: 22476165

Group type: EXPERIMENTAL
Intervention: Static Stretching (SS) - 3 sets of 30-second stretches of the hamstrings, quadriceps, hip flexors, and piriformis.
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Motor Imagery (MI) - visualization of motor activities conducted by a trained technician.
Number of subjects: 13

Group type: COMPARATOR
Intervention: Quiet Rest (QR) - control condition with no specific intervention.
Number of subjects: 13
Study: 21398011

Group type: EXPERIMENTAL
Intervention: 0.05% tranexamic acid in normal saline solution
Number of subjects: 40

Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 40
Study: 18450903

Group type: EXPERIMENTAL
Intervention: Needle-free powder lidocaine delivery system (0.5 mg of lidocaine)
Number of subjects: 579

Group type: COMPARATOR
Intervention: Sham placebo system
Number of subjects: 579
Study: 16525601

Group type: EXPERIMENTAL
Intervention: Jinzhi Hanshuye
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control (tosylchloramide sodium and calcium hydroxide)
Number of subjects: 30
Study: 14612482

Group type: EXPERIMENTAL
Intervention: Epidural analgesia
Number of subjects: 100

Group type: COMPARATOR
Intervention: Parenteral opioids
Number of subjects: 100

Group type: COMPARATOR
Intervention: Thoracic epidural analgesia
Number of subjects: 100
Study: 10756406

Group type: EXPERIMENTAL
Intervention: Febrile convulsion (FC) group
Number of subjects: 103

Group type: COMPARATOR
Intervention: Control group (CC)
Number of subjects: 103
Study: 1723217

Group type: EXPERIMENTAL
Intervention: Interferon
Number of subjects: 47

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study: 7343379

Group type: EXPERIMENTAL
Intervention: Metoprolol RETARD 100 mg
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Metoprolol RETARD 200 mg
Number of subjects: 40
Study: 31066887

Group type: EXPERIMENTAL
Intervention: Infliximab
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 29892933

Group type: EXPERIMENTAL
Intervention: TJ-100 (15 g/day)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 40
Study: 27462894

Group type: EXPERIMENTAL
Intervention: Positive Intermittent Pressure Group
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Volumetric Incentive Spirometer Group
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Both groups (Positive Intermittent Pressure and Volumetric Incentive Spirometer)
Number of subjects: 38
Study: 24268631

Group type: EXPERIMENTAL
Intervention: Nontapered PICC
Number of subjects: 332

Group type: EXPERIMENTAL
Intervention: Reverse tapered PICC
Number of subjects: 332

Group type: EXPERIMENTAL
Intervention: Patients with cancer
Number of subjects: 332

Group type: EXPERIMENTAL
Intervention: Overall
Number of subjects: 332
Study: 22102633

Group type: EXPERIMENTAL
Intervention: 40 mg/kg allopurinol (with an interval of 12 h) starting within 4 h after birth
Number of subjects: 54

Group type: COMPARATOR
Intervention: Control group (no allopurinol treatment)
Number of subjects: 54
Study: 20429491

Group type: EXPERIMENTAL
Intervention: Antibiotics treatment for trichomoniasis (365 women, 83%)
Number of subjects: 2428

Group type: EXPERIMENTAL
Intervention: No treatment for trichomoniasis (63 women, 15%)
Number of subjects: 2428

Group type: COMPARATOR
Intervention: Control group (women without trichomoniasis)
Number of subjects: 2428
Study: 17047001

Group type: COMPARATOR
Intervention: TEC (docetaxel 75 mg/m2, epirubicin 75 mg/m2, cyclophosphamide 500 mg/m2) every 3 weeks
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: EC‐‐>T (E 100 mg/m2, C 600 mg/m2 x 4, then T 100 mg/m2 x 4) every 2 weeks
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: T‐‐>EC (T 100 mg/m2 x 4, then E 100 mg/m2, C 600 mg/m2 x 4) every 2 weeks
Number of subjects: 99
Study: 15758908

Group type: EXPERIMENTAL
Intervention: Dietary intervention in the Polyp Prevention Trial
Number of subjects: 2079

Group type: EXPERIMENTAL
Intervention: Incomplete removal or missed cancer
Number of subjects: 2079
Study: 15526544

Group type: EXPERIMENTAL
Intervention: Spiruline
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 10194726

Group type: EXPERIMENTAL
Intervention: Bar attachments
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Magnet attachments
Number of subjects: 36

Group type: COMPARATOR
Intervention: Ball attachments
Number of subjects: 36

Group type: COMPARATOR
Intervention: Straight bars (reference group)
Number of subjects: 36
Study: 7773814

Group type: EXPERIMENTAL
Intervention: Tendon defect closed (group I)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Tendon defect left open (group II)
Number of subjects: 50
Study: 2227588

Group type: EXPERIMENTAL
Intervention: Cisplatin 100 mg/m2 every 28 days
Number of subjects: 57

Group type: COMPARATOR
Intervention: Carboplatin 400 mg/m2 every 28 days
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Cisplatin second-line treatment
Number of subjects: 57

Group type: COMPARATOR
Intervention: Carboplatin second-line treatment
Number of subjects: 57
Study: 7126440

Group type: EXPERIMENTAL
Intervention: Salbutamol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31178170

Group type: EXPERIMENTAL
Intervention: Stented group
Number of subjects: 92

Group type: COMPARATOR
Intervention: Non-stented group
Number of subjects: 92
Study: 30103785

Group type: EXPERIMENTAL
Intervention: Balancing ACT groups (ACT/PE) plus routine care
Number of subjects: 0

Group type: COMPARATOR
Intervention: Routine care alone
Number of subjects: 0
Study: 26485539

Group type: EXPERIMENTAL
Intervention: Femoral access
Number of subjects: 1399

Group type: COMPARATOR
Intervention: Non-femoral access
Number of subjects: 1399

Group type: EXPERIMENTAL
Intervention: 13.5 Fr catheters
Number of subjects: 1399
Study: 24170763

Group type: EXPERIMENTAL
Intervention: Premixed insulin lispro (insulin lispro mix 25 and/or insulin lispro mix 50)
Number of subjects: 344

Group type: COMPARATOR
Intervention: Basal insulin glargine plus up to three injections of insulin lispro
Number of subjects: 344

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 344
Study: 22455415

Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention
Number of subjects: 5145

Group type: COMPARATOR
Intervention: Diabetes support-and-education program (Control)
Number of subjects: 5145
Study: 21050542

Group type: EXPERIMENTAL
Intervention: Computer-aided diagnosis (CAD) system for quantitative lung fibrosis score
Number of subjects: 129
Study: 18244892

Group type: EXPERIMENTAL
Intervention: Web-based intervention program for weight loss maintenance with features including social support, self-monitoring, written guidelines, and automated reminders.
Number of subjects: 348

Group type: EXPERIMENTAL
Intervention: Automated email and telephone prompts to encourage website log-ins.
Number of subjects: 348
Study: 15986739

Group type: EXPERIMENTAL
Intervention: Unilateral, sub‐threshold extradural motor cortex stimulation (2 8 Volt, 100‐400 microsec., 20‐120 Hz)
Number of subjects: 16
Study: 12913774

Group type: EXPERIMENTAL
Intervention: Dexamethasone (0.6 mg/kg/day in four doses for 48 h)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 22
Study: 10347623

Group type: EXPERIMENTAL
Intervention: Interferon beta-1b
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 8536777

Group type: EXPERIMENTAL
Intervention: DMPA 150 mg single-dose intramuscular injection
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 1780418

Group type: EXPERIMENTAL
Intervention: Alprazolam (1.5 mg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: 2DG (50 mg/kg)
Number of subjects: 10
Study: 6117347

Group type: EXPERIMENTAL
Intervention: Neuroleptics
Number of subjects: 30

Group type: COMPARATOR
Intervention: Benzodiazepines
Number of subjects: 30
Study: 31287255

Group type: EXPERIMENTAL
Intervention: Visual PCNL (Group A)
Number of subjects: 124

Group type: COMPARATOR
Intervention: Conventional PCNL (Group B)
Number of subjects: 124
Study: 29247519

Group type: EXPERIMENTAL
Intervention: Direct oral anticoagulants (DOACs)
Number of subjects: 287
Study: 24149401

Group type: EXPERIMENTAL
Intervention: Oral tranexamic acid (TA) - 1 g starting 2 hours before surgery, 3 g daily in divided doses (1 g every 8 hours) for 5 days
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Intravenous methylprednisolone - single dose of 1 mg/kg at the beginning of surgery
Number of subjects: 75

Group type: COMPARATOR
Intervention: Control group - no treatment
Number of subjects: 75
Study: 24343761

Group type: EXPERIMENTAL
Intervention: E2212 (10-250 mg, single ascending oral doses)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: E2212 (250 mg cohort)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 0
Study: 22931738

Group type: EXPERIMENTAL
Intervention: Mobilaser (attachable, adjustable laser)
Number of subjects: 6

Group type: COMPARATOR
Intervention: No device (control)
Number of subjects: 6
Study: 19237833

Group type: EXPERIMENTAL
Intervention: Proton Pump Inhibitors (PPI)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: H(2) receptor antagonists (H(2)RA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no medication)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: All groups (including PPI, H(2)RA, and control)
Number of subjects: 0
Study: 17437156

Group type: EXPERIMENTAL
Intervention: Indigenous bilayer mesh device
Number of subjects: 84

Group type: COMPARATOR
Intervention: Conventional Prolene hernia system (PHS)
Number of subjects: 84
Study: 15203796

Group type: EXPERIMENTAL
Intervention: Venlafaxine (antidepressant medication) plus standard care (brief counseling and nicotine replacement therapy)
Number of subjects: 134

Group type: COMPARATOR
Intervention: Placebo plus standard care (brief counseling and nicotine replacement therapy)
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Venlafaxine
Number of subjects: 134
Study: 11740317

Group type: EXPERIMENTAL
Intervention: LAIV (live attenuated influenza vaccine)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study: 9512235

Group type: EXPERIMENTAL
Intervention: One-embryo transfer
Number of subjects: 0

Group type: COMPARATOR
Intervention: Two-embryo transfer
Number of subjects: 0
Study: 8040679

Group type: EXPERIMENTAL
Intervention: High-dose methotrexate (HD-MTX) treatment (900 to 3,700 mg/m2 intravenously over 24 hours)
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: More aggressive hydration and alkalinization regimen for subsequent courses
Number of subjects: 134
Study: 2923290

Group type: EXPERIMENTAL
Intervention: Caudal injection of preservative-free morphine sulfate (0.075 mg/kg) in preservative-free normal saline (5-10 ml)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 32
Study: 4914612

Group type: EXPERIMENTAL
Intervention: Phenformin 100mg daily for six weeks
Number of subjects: 41

Group type: COMPARATOR
Intervention: Inert capsules for six weeks
Number of subjects: 41
Study: 31175958

Group type: EXPERIMENTAL
Intervention: Lifestyle intervention
Number of subjects: 720

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 720
Study: 29550173

Group type: EXPERIMENTAL
Intervention: Salad bars installed in schools
Number of subjects: 1193
Study: 28662983

Group type: EXPERIMENTAL
Intervention: Adipose tissue-derived mesenchymal stromal cells (AT-MSCs) at a dosage of 1×10^6/kg (group A, n=9) or 3×10^6/kg (group B, n=5) with cyclosporine and prednisone as first-line therapy
Number of subjects: 14
Study: 25927404

Group type: EXPERIMENTAL
Intervention: eCO measurement
Number of subjects: 410

Group type: COMPARATOR
Intervention: Control group (no eCO measurement)
Number of subjects: 410

Group type: EXPERIMENTAL
Intervention: eCO measurement in smokers (current and former)
Number of subjects: 410

Group type: COMPARATOR
Intervention: Control group (no eCO measurement) in smokers
Number of subjects: 410